Medical Condition News

RSS

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more efficiently diagnose and treat it.

24 Feb 2010

Prednisolone associated with recurrence of CAP after its withdrawal

Patients hospitalized with mild to moderate community-acquired pneumonia (CAP) should not be routinely prescribed prednisolone, a corticosteroid, as it is associated with a recurrence of symptoms after its withdrawal, according to the first randomized double-blind clinical trial to address the subject.

24 Feb 2010

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

AGA conference highlights emerging technologies for digestive and metabolic disorders

The American Gastroenterological Association (AGA) is taking the lead in gastroenterological innovation by conducting "Fostering Innovation and Technology in Digestive and Metabolic Diseases."

24 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Timely treatment and rehabilitation key to proper healing

Sometimes athletes can be their own worst enemy especially when they continue to play following an injury to a foot or ankle. Surgeons presenting at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS) today are discussing athletic injuries and the importance of proper diagnosis, prompt treatment, and full healing and rehabilitation.

23 Feb 2010

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer's disease, may be an early diagnostic biomarker for Alzheimer's disease in healthy adults.

23 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Study proves accuracy of MTWA non-invasive test in identifying patients at risk of arrhythmic events and SCD

Cambridge Heart, Inc., today announced that results of a clinical study presented at the 29th Annual Scientific Meeting of the Belgian Society of Cardiology in Brussels, Belgium, reinforce the value of the Microvolt T-wave Alternans (MTWA) as an accurate non-invasive test to identify patients at risk of arrhythmic events and sudden cardiac death (SCD).

23 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world. To date, NCC has received more than 10 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment. The value of this donation is more than $13 million, and it will help many hundreds of hemophilia patients around the world.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Simple test to check personal cholesterol levels

CardioChek® test system is used by Americans and people in 100 countries around the world to test personal cholesterol levels. Simple, reliable and fast, CardioChek is manufactured by Indianapolis company Polymer Technology Systems, Inc., a leading global provider of point-of-care diagnostic products to the healthcare industry. On February 15th the CardioChek test system was featured on Lifetime Channel’s program, “The Balancing Act,” and will air again on February 22nd and March 15th.

23 Feb 2010

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

NewCardio, Inc., a cardiac diagnostic technology provider, announced today that the Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF). The study results, which discuss the use of CardioBip for improved AF monitoring and detection, are scheduled for oral presentation at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

23 Feb 2010

Key mechanism that makes brain cells become tumorous identified

Researchers from the Peninsula Medical School in Plymouth (UK), the Memorial Sloan-Kettering Cancer Center in New York, Cornell University in New York, Weil Medical College in New York and the Center for Neural Tumour Research in Los Angeles, have for the first time identified a key mechanism that makes certain cells become tumorous in the brain. The resulting tumours occur most often spontaneously but can also occur in numbers as part of the inherited disease Neurofibromatosis type 2.

23 Feb 2010

Medical Condition News

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Prednisolone associated with recurrence of CAP after its withdrawal

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

AGA conference highlights emerging technologies for digestive and metabolic disorders

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Findings suggest bitter melon extract may help in preventing breast cancer

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Timely treatment and rehabilitation key to proper healing

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

New Barts Cancer Research UK Centre launched

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Study proves accuracy of MTWA non-invasive test in identifying patients at risk of arrhythmic events and SCD

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Simple test to check personal cholesterol levels

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

Key mechanism that makes brain cells become tumorous identified

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News